Publications by authors named "Hans Rebscher"
Purpose: The primary objective of this phase I trial was to establish the safety profile and pharmacokinetics of cixutumumab administered every 2 weeks (q2w) or every 3 weeks (q3w) in Japanese patients with advanced solid tumors. Exploratory analyses included preliminary antitumor activity.
Methods: Patients received intravenous cixutumumab q2w or q3w (6-week cycle) in a standard 3 + 3 study design.
Article Synopsis
- A new microarray platform has been created that lets scientists quickly do experiments with tiny pieces of DNA right at their lab bench.
- This platform can make special DNA probes using light, allowing researchers to customize their experiments in just a few hours.
- The results from experiments on this platform showed that it works really well, providing accurate and consistent data about gene activity, similar to other advanced methods used in labs.